Apogee Therapeutics, Inc. (APGE)

53,37 +0,45 (+0,84%) In data: 03:06PM EDT. Mercato aperto.

Apogee Therapeutics, Inc.

221 Crescent Street
Building 17 Suite 102b
Waltham, MA 02453
United States
650-394-5230
https://www.apogeetherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 91

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Michael Thomas Henderson M.D.	CEO & Director	1,17M	N/D	1990
Ms. Jane Pritchett V. Henderson	Chief Financial Officer	843,64k	N/D	1966
Dr. Carl Linden Dambkowski M.D.	Chief Medical Officer	870,83k	N/D	1986
Ms. Noel Kurdi	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Matthew Batters J.D.	Chief Legal Officer & Corporate Secretary	N/D	N/D	1976
Ms. Emily Cox	VP & Head of People	N/D	N/D	N/D
Dr. Rebecca Dabora Ph.D.	Chief Development Officer	N/D	N/D	1960
Ms. Wendy Aspden-Curran	Senior Vice President of Clinical Operations	N/D	N/D	N/D
Dr. Drew Badger Ph.D.	Senior VP and Head of Regulatory Affairs & Toxicology	N/D	N/D	N/D
Ms. Monica Forbes	Senior Vice President of Finance	N/D	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Apogee Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.